Leveraging CTCs for Innovative Delivery of FVIII

rFVIII PFM

Oral Delivery

2002

Submitted for Regulatory Approval

2003 and Beyond

Sustained Release

Oral/Nasal Delivery

Improved Half-life

Improved Delivery

Continue to Innovate and Improve Leadership

Position in Hemophilia Care

Microspheres

Improved Devices

FVIII Mimetics

FVIII Binding Proteins

New Formulations

Previous slide

Next slide

Back to first slide

View graphic version